Medicare weight-loss coverage drives 700,000 new patients to GLP-1s

CEO Dave Ricks confirmed in an interview with CNBC that 70% of these new seniors are currently prescribed Eli Lilly medications. He characterized the initial rollout as encouraging, noting that the broader market expansion aligns with the company’s internal projections for the sector.

This growth is fueled by a temporary program known as Bridge, which provides eligible beneficiaries access to weight-loss therapies for a $50 monthly co-pay. While the program serves as a critical entry point for those aged 65 and older or individuals with disabilities, the data underscores a tightening race between Lilly and its primary competitor, Novo Nordisk, as both firms vie for dominance in the newly accessible Medicare demographic.